SynthesisBMC gastroenterology2025
Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?Medical sciences (Basel, Switzerland) · 2026Review
- GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study.Scientific reports · 2026Article
- Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have shown an increase in obesity prevalence in the inflammatory bowel disease (IBD) population. The popularity of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) has increased in recent years due to their effectiveness in weight management. In this comprehensive review, we evaluate the efficacy of GLP-1 RAs in the management of obesity in patients with IBD.
methodsWe performed a systematic search of PubMed, Embase, Scopus, and Web of Science up to October 2025 for studies that reported changes in anthropometric variables in IBD cases treated with GLP-1 RAs. The primary outcome was weight loss after treatment, and the secondary outcome was changes in patients' metabolic profiles. We pooled the mean raw changes (MRAW) in weight, body mass index (BMI), Glycated hemoglobin (HbA1c), Total cholesterol, high-density lipoprotein (HDL), and Low-density lipoprotein (LDL) from baseline to follow-up. This study was registered in PROSPERO (CRD420251063158).
resultsOverall, eight retrospective cohort studies involving 1236 patients were included. The pooled weight change following GLP-1 RAs treatment was - 5.71 Kg (95% CI, -9.56 to -1.86; P = 0.01; I² = 78.0%). The weight loss was also significant in the semaglutide subgroup (MRAW: -5.59 Kg; 95% CI, -10.37 to -0.81; P = 0.03; I² = 80.0%). Furthermore, the pooled MRAW of three studies on BMI changes showed a significant reduction (-2.18 Kg/m
conclusionThe GLP-1 RAs could be an effective option for obesity management in IBD. However, the robustness of the current study's results is limited by potential bias in the included studies and small sample sizes in the secondary outcomes analysis. Further prospective studies are needed prior to broader prescription of GLP-1 RAs in the IBD population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.